The Levita MARS system is a minimally invasive surgical platform designed with a compact footprint to fit into the existing operating rooms and leverages both magnets and machines to improve patient outcomes in high-volume abdominal surgeries
Levita MARS System is a minimally invasive surgical platform. (Credit: PRNewswire/ Levita)
US-based medical technology company Levita Magnetics has received the US Food and Drug Administration (FDA) approval for its MARS platform.
The Levita MARS system is a minimally invasive surgical platform designed to improve patient outcomes in high-volume abdominal surgeries.
It comes with a compact design to fit into the existing operating rooms.
The platform leverages both magnets and machines to reduce the number of incisions and enables surgeons to have complete control during laparoscopic procedures.
Levita designed the new MARS based on the success of its previous commercial product, the Levita Magnetic Surgical System.
MARS delivers the same patient benefits as Magnetic Surgical System, while providing surgeons with enhanced control of surgical instruments and enabling hospitals to incorporate the new technology easily, said the medical technology company.
Levita Magnetics surgeon, founder, and CEO Alberto Rodriguez-Navarro said: “Today marks a significant milestone in Levita’s mission to provide more patients access to state-of-the-art surgical technology.
“MARS is poised to revolutionize surgical options for a broad range of patients. With this FDA clearance, we eagerly anticipate making a substantial impact across the value chain.”
According to the company, MARS aims to deliver less-invasive surgery with reduced incisions, which results in less pain, faster recovery, and fewer scars to the patients.
The surgical platform enables the surgeons to benefit from full control over the laparoscopic view, eliminating the need for an additional assistant.
Also, MARS provides benefits over the Magnetic Surgical System by enabling the retraction of large tissues and organs such as the liver, gallbladder, prostate, and colon.
The surgical platform helps hospitals and ASCs benefit from enhanced performance, effective deployment of OR personnel, and a differentiated patient experience, said Levita.
Levita chairperson Maria Sainz said: “MARS by Levita has the potential to reshape the surgical industry and forever change medical innovation.
“Our pioneering MARS platform gives patients and surgeons a transformative tool that will usher in a fundamental shift in surgery for years to come.
“Levita’s system can aid in surgeon proficiency and efficiency, and can reduce the need for assistive personnel, signalling a major achievement not only for Levita but for surgical care.”